Searched for: in-biosketch:yes
person:mandas08
Non-steroidal Immune Modulating Therapies and Reduced Risk of Adverse Cardiovascular Events in Dermatomyositis and Polymyositis: A Cohort Study in the All of Us Research Program
Shah, Jill T; Shah, Keya T; Mandal, Soutrik; Garshick, Michael S; Femia, Alisa N
PMID: 39547326
ISSN: 1097-6787
CID: 5753932
Characterizing Narrowband UVB Post-Treatment Erythema: Standardization of a Burn
Lau, Megan; Cohen, Niki; Nagler, Arielle; Friedman, Steven; Mandal, Soutrik; Zampella, John G
PMID: 39522727
ISSN: 1097-6787
CID: 5752452
Epidemiology of Patients With Dance-Related Injuries Presenting to Medical Staff at Breaking Competitions in the United States, 2021-2023
Honrado, Joshua; Lee, Scott; Ngor, Aaron; Lee, TeeJay; Mandal, Soutrik
PMID: 39917908
ISSN: 2374-8060
CID: 5784352
Sarcoidosis-Specific Cutaneous Lesion Distribution in Clinical Assessment for Cardiac Sarcoidosis
Sikora, Michelle; Obijiofor, Chinemelum; Osofsky, Angelo; Liu, Lynn; Mandal, Soutrik; Lo Sicco, Kristen I; Caplan, Avrom S
PMCID:11840637
PMID: 39745713
ISSN: 2168-6084
CID: 5805602
Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib
Needle, Carli D; Yin, Lu; Young, Trevor K; Friedman, Steven; Mandal, Soutrik; Segal, Devorah; Yohay, Kaleb H; Lakdawala, Nikita R; Oza, Vikash S
BACKGROUND:Binimetinib and selumetinib are two mitogen-activated protein kinase kinase (MEK) inhibitors used to treat low-grade gliomas and plexiform neurofibromas. Cutaneous toxicities are commonly associated with MEK inhibitors; however, limited studies have examined cutaneous effects in a pediatric population or whether toxicities vary between MEK inhibitors. METHODS:We conducted an IRB-approved, single-center, retrospective review of pediatric neuro-oncology patients on binimetinib or selumetinib who presented to NYU from April 2016 through July 2022. RESULTS:Forty-six children met inclusion criteria (23 females, 23 males) with a mean age of 11.7 years. Thirty-three were treated with binimetinib and 13 with selumetinib. Dermatologic adverse events were encountered in 97.8% of the cohort, and the most common were acneiform eruption (63.0%), paronychia (58.7%), and xerosis (54.3%). Children 12 years and older were more likely to have acneiform eruption (p < 0.001) and seborrheic dermatitis (p < 0.001), while children under 12 were more likely to have xerosis (p = 0.037). The incidence of cutaneous adverse events was significantly different between MEK inhibitors for folliculitis and hair pigment dilution (39.4% binimetinib, 0% selumetinib, p = 0.009). Significantly, more patients required MEK inhibitor dose reduction/hold on binimetinib (87.9%) than selumetinib (46.2%) (p = 0.006). Severity of cutaneous disease was not associated with tumor response. CONCLUSIONS:Our study confirms dermatologic adverse events are common in children on MEK inhibitors. Age appears to be associated with increased likelihood of certain cutaneous reactions. Overall, the selumetinib patients in our cohort presented with less severe adverse events and decreased risk of MEK inhibitor dose reduction/hold. Our results will aid clinicians in providing appropriate counseling, treatments, and improved preventive care.
PMID: 39511793
ISSN: 1525-1470
CID: 5752132
Ambient ultraviolet A, ultraviolet B and risk of melanoma in a nationwide United States cohort, 1984-2014
Cahoon, Elizabeth K; Mandal, Soutrik; Pfeiffer, Ruth M; Wheeler, David C; Sargen, Michael R; Alexander, Bruce H; Kitahara, Cari M; Linet, Martha S; Mai, Jim Z
BACKGROUND:Ultraviolet radiation (UVR) exposure is the primary risk factor for melanoma although the relationship is complex. Compared to radiation from UVB wavelengths, UVA makes up a majority of the surface solar UVR, penetrates the skin more deeply, is the principal range emitted by tanning beds, and is less filtered by sunscreens and window glass. Few studies have examined the relationship between ambient UVA and UVB and melanoma risk. METHODS:Incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were estimated for the association between satellite-based ambient (based on residential history) UVA, UVB and melanoma in non-Hispanic White participants using data from the United States Radiologic Technologists study, a large, nationwide prospective cohort. Associations of UVA and UVB quartile (Q) were examined in mutually adjusted and stratified models, additionally adjusted for demographic and sun sensitivity characteristics. RESULTS:There were 837 incident melanoma cases among 62,785 participants. Incidence of melanoma was statistically significantly increased for the highest quartile of childhood UVA exposure after adjustment for UVB (IRR = 2.82; 95%CI:1.46,5.44), but not for higher childhood UVB after adjustment for UVA. Childhood UVA was associated with increased melanoma risk within strata of UVB. Childhood UVB was not associated with melanoma after adjustment for UVA, but there was some evidence of lower risk with increased lifetime ambient UVB after UVA adjustment. CONCLUSIONS:Melanoma risk was elevated among participants living in locations with high annual childhood and lifetime UVA after controlling for UVB. With confirmation, these findings support increased protection from solar UVA for melanoma prevention.
PMID: 39115885
ISSN: 1460-2105
CID: 5730842
Investigating QTc Prolongation with Hydroxychloroquine Use Among Patients with Cutaneous Sarcoidosis: A Multi-Center, Retrospective Study
Obijiofor, Chinemelum E; Sikora, Michelle; Liu, Lynn; Stern, Marleigh J; Hena, Kerry M; Mazori, Daniel R; Friedman, Steven; Mandal, Soutrik; Caplan, Avrom S
PMID: 38885839
ISSN: 1097-6787
CID: 5671932
To evaluate hypertrichosis with low dose oral minoxidil and spironolactone combination therapy for alopecia [Letter]
Nohria, Ambika; Desai, Deesha; Sikora, Michelle; Mandal, Soutrik; Caplan, Avrom; Shapiro, Jerry; Sicco, Kristen I Lo
Low dose oral minoxidil (LDOM) is an efficacious and safe treatment for alopecia, however, a notable side effect is hypertrichosis. Spironolactone, known for treating hirsutism, is also used off-label for the treatment of certain forms of alopecia and may reduce LDOM-induced hypertrichosis. We performed a retrospective review of 54 patients seen at NYU Langone Health and compared hypertrichosis rates in female alopecia patients on LDOM monotherapy versus those on combination therapy with spironolactone. Among 54 patients, 37 received LDOM alone and 17 received the combination. Hypertrichosis developed in 33.3% of patients, with lower rates in the combination group (17.6% vs. 40.5% for monotherapy). Although not statistically significant, the trend suggests spironolactone may mitigate hypertrichosis. The study highlights the potential of combination therapy to address hypertrichosis and calls for larger studies to confirm these findings.
PMID: 39133327
ISSN: 1432-069x
CID: 5697112
Response to "Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: a retrospective study" [Letter]
Desai, Deesha; Nohria, Ambika; Sikora, Michelle; Mandal, Soutrik; Shapiro, Jerry; Caplan, Avrom S; Garshick, Michael; Lo Sicco, Kristen
PMID: 38499178
ISSN: 1097-6787
CID: 5640192
Combating "dread shed": The impact of overlapping topical and oral minoxidil on temporary hair shedding during oral minoxidil initiation
Nohria, Ambika; Desai, Deesha; Sikora, Michelle; Mandal, Soutrik; Shapiro, Jerry; Lo Sicco, Kristen
BACKGROUND/UNASSIGNED:Low dose oral minoxidil (LDOM) is a preferred treatment for alopecia due to ease of use and efficacy. While LDOM is typically well tolerated, patients may experience a temporary increase in hair shedding starting treatment, colloquially regarded as "dread shed". One proposed method to combat this is to overlap therapies by maintaining use of topical minoxidil when initiating LDOM. OBJECTIVE/UNASSIGNED:To evaluate the impact of maintaining topical minoxidil when initiating LDOM on "dread shed". METHODS/UNASSIGNED:We performed a retrospective chart review of patients seen at New York University Langone Health Dermatology from January 1, 2008 to August 1, 2023 prescribed LDOM. RESULTS/UNASSIGNED:A total of 115 patients met inclusion criteria, of whom 37 maintained use of topical minoxidil when initiating LDOM. Six patients experienced "dread shed" when initiating LDOM, 2 of whom overlapped therapies. We did not find that overlapping therapies had a significant impact on decreasing rates of "dread shed". LIMITATIONS/UNASSIGNED:Limitations include retrospective design, sample size, and subjective patient-reported assessment of hair shedding. CONCLUSIONS/UNASSIGNED:A total of 5.2% of patients experienced dread shed, which is lower than previously reported in literature. Maintaining topical minoxidil during LDOM initiation does not significantly impact "dread shed". This remains a significant side effect deserving of further research.
PMCID:11067493
PMID: 38707927
ISSN: 2666-3287
CID: 5733852